Press release: ash: sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients

Ash: sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients new analysis from the imroz phase 3 study of sarclisa-vrd demonstrated higher and sustained mrd negativity rates in transplant-ineligible ndmm patients versus vrd alone new detailed results from the gmmg-hd7 phase 3 study of sarclisa-rvd induction therapy resulted in a significant and clinically meaningful pfs benefit with deeper mrd negativity in transplant-eligible ndmm patients results support the benefit of sarclisa-based combinations to patients in the front-line setting and the ongoing use of mrd negativity as a potential surrogate endpoint for pfs in mm research paris, december 9, 2024. new data from three oral presentations, which demonstrated significant clinical benefit with sarclisa-based quadruplets in newly diagnosed multiple myeloma (ndmm) patients were featured at the 66th american society of hematology (ash) annual meeting & exposition in san diego, ca, us.
ASH Ratings Summary
ASH Quant Ranking